ArticleAIDS research and therapy2025
Dolutegravir rollout for treatment of HIV with a focus on advanced disease and tuberculosis coinfection: findings from rural KwaZulu-Natal, South Africa (2019-2023).
Article in AIDS research and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of the Scale-Up of Dolutegravir on Retention in Care, Risk of Developing Tuberculosis and Viral Load Suppression Among People Living With HIV: Analysis of Routine HIV Clinical Data in Rural KwaZulu-Natal, South Africa (2019-23).Open forum infectious diseases · 2026Article
- Maintain, not obtain: rethinking HIV care in sub-Saharan Africa in the era of dolutegravir.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundWhile Dolutegravir (DTG) containing antiretroviral therapy (ART) has become the preferred regimen for people living with HIV (PLHIV), the pace and equity of its adoption, especially among subgroups with tuberculosis (TB) symptoms and advanced HIV disease (AHD), remain understudied in high-burden settings like rural KwaZulu-Natal (KZN), South Africa. This study describes the transition to DTG and examines the effect of TB and AHD (CD4 count < 200 cells/mm
methodsWe conducted a longitudinal cohort analysis using routine HIV program data from 69,916 PLHIV aged ≥ 15 years attending 19 HIV clinics in rural KZN, between 1st October 2019, and December 31st 2023. Kaplan-Meier analysis estimated time to DTG transition, while a multivariate mixed-effect Cox proportional hazards model evaluated factors associated with transitioning to DTG.
resultsOf the 69,916 PLHIV included in the cohort, 49,365 (70.6%) were female, and the median age of the PLHIV was 40 years (IQR: 32-49). By the end of the follow-up period, 70.9% (n = 49,598) of the PLHIV transitioned to DTG in 165,880 person-years. The median time to DTG transition was 14 months among PLHIV without TB symptoms, compared to 22 months among those with TB symptoms. Similarly, PLHIV with CD4 counts ≥ 350 cells/mm³ transitioned at a median of 14 months, while those with CD4 < 200 cells/mm³ transitioned 14 months later. The likelihood of transitioning to DTG was 22% lower among PLHIV with TB symptoms (aHR = 0.78, 95% CI: 0.76, 0.82) compared to their counterparts without TB symptoms, and 43% lower among PLHIV with AHD (aHR = 0.57, 95% CI: 0.54,1.59) compared to their counterparts without AHD.
conclusionOur analysis showed that over a quarter of the PLHIV in rural KZN remained on non-DTG-containing regimens by 31st December 2023. PLHIV coinfected with TB and having AHD transitioned at a slower pace than their counterparts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.